Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study

[1]  G. London,et al.  Long-term treatment with biosimilar epoetin-α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study , 2017, Clinical nephrology.

[2]  J. Cannata-Andía,et al.  The challenge of controlling phosphorus in chronic kidney disease. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  G. London,et al.  Risk-based individualisation of target haemoglobin in haemodialysis patients with renal anaemia in the post-TREAT era: theoretical attitudes versus actual practice patterns (MONITOR-CKD5 study) , 2015, International Urology and Nephrology.

[4]  E. Vittinghoff,et al.  Health status as a potential mediator of the association between hemodialysis vascular access and mortality. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  G. London,et al.  A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: background and methodology of the MONITOR-CKD5 study , 2013, Internal and Emergency Medicine.

[6]  Wim Van Biesen,et al.  Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  J. Adamson,et al.  Notice , 2012, Kidney International Supplements.

[8]  I. Macdougall,et al.  Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  M. Tonelli,et al.  Oral phosphate binders in patients with kidney failure. , 2010, The New England journal of medicine.

[10]  J. Bragg-Gresham,et al.  Dialysis Outcomes and Practice Patterns Study estimate of patient life-years attributable to modifiable haemodialysis practices in Sweden , 2010, Scandinavian journal of urology and nephrology.

[11]  R. Wolfe,et al.  Facility hemodialysis vascular access use and mortality in countries participating in DOPPS: an instrumental variable analysis. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  G. Fonarow,et al.  Fluid Retention Is Associated With Cardiovascular Mortality in Patients Undergoing Long-Term Hemodialysis , 2009, Circulation.

[13]  C. Combe,et al.  Gain de vie potentiel pour les patients hémodialysés français attribuable aux modifications des pratiques et la mise en conformité avec les cibles recommandées : une estimation permise par l’étude DOPPS , 2008 .

[14]  Rob Horne,et al.  A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease , 2008, BMC nephrology.

[15]  Kdoqi.  KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. , 2007 .

[16]  J. Bragg-Gresham,et al.  DOPPS estimate of patient life years attributable to modifiable hemodialysis practices in Canada. , 2007, Nephrology news & issues.

[17]  N. Lameire,et al.  DOPPS ESTIMATE OF PATIENT LIFE YEARS ATTRIBUTABLE TO MODIFIABLE HAEMODIALYSIS PRACTICES IN BELGIUM , 2007, Acta clinica Belgica.

[18]  Robert A. Wolfe,et al.  DOPPS Estimates of Patient Life Years Attributable to Modifiable Hemodialysis Practices in the United States , 2004, Blood Purification.

[19]  G. Kaysen.  Serum albumin concentration in dialysis patients: why does it remain resistant to therapy? , 2003, Kidney international. Supplement.

[20]  S. Fukuhara,et al.  Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS. , 2003, Kidney international.

[21]  Keith C. Norris,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  E W Young,et al.  Type of vascular access and mortality in U.S. hemodialysis patients. , 2001, Kidney international.

[23]  J. M. Cruz,et al.  Estimación, según el estudio DOPPS, de los años de vida de pacientes atribuibles a las prácticas de hemodiálisis modificables en España. , 2007 .

[24]  J. Berns,et al.  KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  H. Feldman,et al.  Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[26]  F. Port,et al.  [Dialysis Outcomes and Practice Patterns Study: data on the use of central venous catheters in chronic hemodialysis]. , 2001, Nephrologie.

[27]  R. Wolfe,et al.  The Dialysis Outcomes and Practice Patterns Study (DOPPS): An international hemodialysis study , 2000 .